Skip to main content

Optimizing a deployable high efficacy malaria vaccine

Objective

A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates.
Our approach tackles the toughest problems in malaria vaccine design: choice of the best antigens, attaining high immunogenicity, avoiding polymorphic antigens and increasing the durability of vaccine immunogenicity and efficacy.
We take advantage of several recent advances in vaccinology and adopt some very new technologies: sequencing malaria peptides eluted from the HLA molecules, parasites expressing multiple transgenes, multi-antigen virus-like particles constructed with new bonding technologies, delayed release microcapsules, and liver-targeted immunisation with vaccine vectors.
We enhance our chances of success by using a multi-stage multi-antigen approach, by optimising the magnitude and durability of well-characterised immune responses to key antigens, and using stringent infectious challenges and functional assays as established criteria for progression at each stage.
The consortium comprises many of the foremost researchers in this field in Europe with leading groups in the USA, Australia and Africa. We link to EDCTP programmes and harmonise our timeline to fit with the recent roadmaps for malaria vaccine development. We include a major pharma partner and several excellent European biotech companies helping enhance Europe’s leading position in the commercial development of vaccines.
This ambitious and exciting programme should have a high chance of success in tackling the major global health problem posed by malaria.

Field of science

  • /medical and health sciences/health sciences/infectious disease/malaria
  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 13 051 666,25

Participants (15)

STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 4 427 500
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 1 175 000
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
SORBONNE UNIVERSITE

Participation ended

France
EU contribution
€ 0
Address
21 Rue De L'ecole De Medecine
75006 Paris
Activity type
Higher or Secondary Education Establishments
GENOME RESEARCH LIMITED
United Kingdom
EU contribution
€ 250 000
Address
The Gibbs Building, Euston Road 215
NW1 2BE London
Activity type
Research Organisations
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
France
EU contribution
€ 183 775
Address
Boulevard De Dunkerque 44 Cs 90009
13572 Marseille
Activity type
Research Organisations
STATENS SERUM INSTITUT
Denmark
EU contribution
€ 250 000
Address
Artillerivej 5
2300 Kobenhavn S
Activity type
Research Organisations
UNIVERSITE DE LAUSANNE
Switzerland
EU contribution
€ 0
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
NOVAVAX AB
Sweden
EU contribution
€ 150 000
Address
Kungsgatan 109
753 18 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EXPRES2ION BIOTECHNOLOGIES APS
Denmark
EU contribution
€ 25 000
Address
Agern Alle 1
2970 Horsholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
IMAXIO SA

Participation ended

France
EU contribution
€ 5 158,05
Address
Rue Saint Roch 5/7
75001 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
JAMES COOK UNIVERSITY
Australia
EU contribution
€ 0
Address
James Cook University
4811 Townsville
Activity type
Higher or Secondary Education Establishments
PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH
United States
EU contribution
€ 25 000
Address
Leary Way Nw 1455
98107-5136 Seattle Wa
Activity type
Research Organisations
UNITED KINGDOM RESEARCH AND INNOVATION

Participation ended

United Kingdom
EU contribution
€ 0
Address
Polaris House North Star Avenue
SN2 1FL Swindon
Activity type
Research Organisations
JANSSEN VACCINES & PREVENTION BV
Netherlands
EU contribution
€ 25 000
Address
Archimedesweg 4
2333 CN Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OSIVAX SAS
France
EU contribution
€ 19 841,95
Address
4 Rue De Copenhague
75008 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)